Advances in the Treatment of Multiple Sclerosis.

Multiple sclerosis is a relatively common, immune-mediated neurologic disease of the central nervous system that can cause significant disability and lead to reduced quality of life. There are several currently approved disease-modifying therapies, and more in the pipeline being developed and tested. As the field learns more about the pathophysiology and natural course of the disease, the treatment approaches are also being investigated. This article reviews data on available treatments along with a discussion of future treatment targets under investigation.

• Publication year

  2021

• Venue

  Neurologic clinics

• Publication date

  2021-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ncl.2020.09.002PMID 33223085PMCID PMC7687744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

  2020cited by this paper
• Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

  2020cited by this paper
• The prevalence of MS in the United States

  2019cited by this paper
• Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

  2019cited by this paper
• The potential use of mesenchymal stem cells for the treatment of multiple sclerosis.

  2019influential reference
• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

  2019cited by this paper
• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

  2019cited by this paper
• Progressive multiple sclerosis: from pathophysiology to therapeutic strategies

  2019cited by this paper
• Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.

  2019influential reference
• Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

  2019cited by this paper
• Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

  2019influential reference
• Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

  2019cited by this paper
• Progressive multiple sclerosis: latest therapeutic developments and future directions

  2019cited by this paper
• Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells

  2019cited by this paper
• Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab

  2018cited by this paper
• Efficacy and safety of natalizumab extended interval dosing.

  2018cited by this paper
• Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis

  2018cited by this paper
• Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

  2018cited by this paper
• Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations

  2018cited by this paper
• Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

  2018cited by this paper
• Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management

  2018cited by this paper
• Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

  2018cited by this paper
• Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

  2017cited by this paper
• Lipoic acid in secondary progressive MS

  2017cited by this paper
• Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.

  2017cited by this paper
• Clemastine fumarate for promotion of optic nerve remyelination.

  2017cited by this paper
• NEDA treatment target? No evident disease activity as an actionable outcome in practice.

  2017cited by this paper
• Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis

  2017cited by this paper
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

  2017cited by this paper
• Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

  2016cited by this paper
• Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study

  2016cited by this paper
• Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.

  2016cited by this paper
• Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

  2016cited by this paper
• MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

  2016cited by this paper
• Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Defining the clinical course of multiple sclerosis

  2014cited by this paper
• Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

  2014cited by this paper
• Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.

  2014cited by this paper
• Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

  2014cited by this paper
• Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

  2014cited by this paper
• Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

  2012cited by this paper
• Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

  2012cited by this paper
• Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

  2012cited by this paper
• A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

  2010cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008influential reference
• Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial

  2007cited by this paper
• Placebo-controlled multicentre randomised trial of interferon (cid:1) -1b in treatment of secondary progressive multiple sclerosis

  2005cited by this paper
• Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

  2004cited by this paper
• A controlled trial of natalizumab for relapsing multiple sclerosis.

  2003cited by this paper
• Interferon β-1a in primary progressive MS

  2003cited by this paper
• Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

  2003cited by this paper
• Randomized controlled trial of interferon- beta-1a in secondary progressive MS

  2001cited by this paper
• Randomized controlled trial of interferon-beta-1a in secondary progressive MS

  2001cited by this paper
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

  1998cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

  1993cited by this paper

• Real-world effectiveness and safety of ofatumumab in relapsing multiple sclerosis: A multicenter cohort study.

  2026cites this paper
• The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus

  2025cites this paper
• Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation

  2025cites this paper
• Personalized therapy in multiple sclerosis: an Italian Delphi consensus

  2025cites this paper
• Multiple sclerosis management: therapies and future perspectives

  2025cites this paper
• A New Serological Autoantibody Signature Associated with Multiple Sclerosis

  2025cites this paper
• Exploring the Perspectives of Healthcare Consumers Towards the Integration of Nutrition in Routine Multiple Sclerosis Care: A Qualitative Study

  2025cites this paper
• Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges

  2025cites this paper
• Out-of-Pocket and Total Health Care Costs Among Commercially Insured Adults and Children With Multiple Sclerosis.

  2025cites this paper
• SMART-MC: Characterizing the Dynamics of Multiple Sclerosis Therapy Transitions Using a Covariate-Based Markov Model

  2025cites this paper
• Increased efficacy of adipose-derived mesenchymal stem cells transduced with klotho in differentiation and maturation of oligodendrocytes in a mouse model of experimental autoimmune encephalomyelitis.

  2025cites this paper
• Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register.

  2024cites this paper
• Effectiveness of robotic rehabilitation for gait and balance in people with multiple sclerosis: a systematic review

  2024cites this paper
• Overview of emerging therapies for demyelinating diseases

  2024cites this paper
• Patient iPSC models reveal glia-intrinsic phenotypes in multiple sclerosis.

  2024cites this paper
• Long‐Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries

  2024cites this paper
• Disease-modifying therapies as positive predictors of quality of life for Sudanese patients with multiple sclerosis: a cross-sectional study

  2024cites this paper
• Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges.

  2024cites this paper
• Adherence, Persistence, Switching and Costs of Injectable and Oral Therapies for Multiple Sclerosis. Real Life Analysis Over 6 Years of Treatment

  2024cites this paper
• Highly Active Relapsing-Remitting Multiple Sclerosis with Neurofibromatosis Type 1: Radiological Aspects and Therapeutic Challenges – Case Report

  2024cites this paper
• Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption

  2024cites this paper
• Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing.

  2024cites this paper
• Neuroinflammation-on-a-chip for multiple sclerosis research: a narrative review

  2024cites this paper
• Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases

  2023cites this paper
• THE CONTRIBUTION OF DIFFUSION TENSOR IMAGING TO CONVENTIONAL MAGNETIC RESONANCE IMAGING IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS PATIENTS

  2023cites this paper
• Carboplatin ameliorates the pathogenesis of experimental autoimmune encephalomyelitis by inducing T cell apoptosis.

  2023cites this paper
• Course of therapy in patients with active relapsing-remitting multiple sclerosis despite first-line treatment

  2023cites this paper
• Patient iPSC models reveal glia-intrinsic phenotypes in multiple sclerosis

  2023cites this paper
• Dihydroartemisinin Promotes Neural Stem Cell Differentiation into Oligodendrocytes via STAT6/Chi3l3 Signaling Pathway in Microglia

  2023cites this paper
• Alterations of Oligodendrocyte and Myelin Energy Metabolism in Multiple Sclerosis

  2023cites this paper
• Synthesis and Characterization of Edaravone Analogues as Remyelinating Agents and Putative Mechanistic Probes

  2023cites this paper
• Evaluation of different phytochemicals from Cannabis sativa against Myelin oligodendrocyte glycoprotein receptor

  2023cites this paper
• Therapeutic Potential of Combined Therapy of Vitamin A and Vitamin C in the Experimental Autoimmune Encephalomyelitis (EAE) in Lewis Rats

  2022cites this paper
• Standardized Systematic Description of Provision of Care for Multiple Sclerosis at a Local Level: A Demonstration Study.

  2022cites this paper
• The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis

  2022cites this paper
• Diagnosis and classification of optic neuritis.

  2022cites this paper
• The Design, Development, and Testing of a Virtual Reality Device for Upper Limb Training in People With Multiple Sclerosis: Single-Center Feasibility Study

  2022cites this paper
• Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants.

  2022cites this paper
• The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis.

  2022cites this paper
• Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies.

  2022cites this paper
• Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion

  2022cites this paper
• Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

  2022cites this paper
• Cortical and white matter lesion topology influences focal corpus callosum atrophy in multiple sclerosis

  2022cites this paper
• Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation

  2022cites this paper
• Multiple Sclerosis

  2021cites this paper
• Piperine Improves Experimental Autoimmune Encephalomyelitis (EAE) in Lewis Rats Through its Neuroprotective, Anti-inflammatory, and Antioxidant Effects

  2021cites this paper
• Hypoxia-Inducible Factor (HIF) in Ischemic Stroke and Neurodegenerative Disease

  2021cites this paper
• Matrine treatment induced an A2 astrocyte phenotype and protected the blood-brain barrier in CNS autoimmunity.

  2021cites this paper
• Molecular Examination of Differentially Expressed Genes in the Brains of Experimental Autoimmune Encephalomyelitis Mice Post Herceptin Treatment

  2021cites this paper
• Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

  2021cites this paper
• Discovery of PIPE-359, a Brain-Penetrant, Selective M1 Receptor Antagonist with Robust Efficacy in Murine MOG-EAE.

  2020cites this paper